Biotech

Today, access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between ABBVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. These genetic data have been paired with detailed health information to create this browsable resource.

The collaboration between AbbVie, Biogen and Pfizer to make these data available highlights the importance of working together to advance science. The companies engaged with the Broad Institute for data processing and to conduct single variant and gene-based association testing with nearly 4,000 UK Biobank phenotypes to identify associations between distinct genes or genetic variants and disease. In line with the collaboration members' commitment to openness, these results can now be accessed freely via the new browser. This browser will enable scientists worldwide to explore and utilize the data for their respective areas of interest in accordance with UK Biobank's terms of use.

"Human genetics has been foundational to understanding disease etiologies and is a first step to finding solutions to some of humanity's most devastating diseases," said Professor Sir Rory Collins, UK Biobank Principal Investigator and Chief Executive. "Our hope is that this information will allow researchers to better understand the human genome and identify therapeutic strategies that can specifically target the underlying causes of disease."

"We are proud to be involved in this exciting project and believe the collected information will yield important insights for the global scientific community," said Anthony Philippakis, Chief Data Officer at the Broad Institute. "By combining the expertise of the healthcare industry and the non-profit research community, we can carefully assess how biomedical data at this unprecedented scale is best utilized and hopefully accelerate the path from genetic discoveries towards novel therapeutics."

The UK Biobank whole exome sequencing data has been generated as part of the UK Biobank Exome Sequencing Consortium, formed in 2018, which, in addition to AbbVie, Biogen and Pfizer, includes additional industry partners, supporting a trend across the industry to collaborate in a precompetitive manner for generating the source data for an improved understanding of human biology and disease.

The browser can be accessed via https://genebass.org .

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter , Facebook , Instagram , YouTube and LinkedIn .

AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

We routinely post information that may be important to investors on our website at www.biogen.com . Follow us on social media – Twitter , LinkedIn , Facebook , YouTube .

Biogen Safe Harbor
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about a new platform to access results from analyses of whole exome sequencing data from 300,000 research participants from the UK Biobank and the related results; and the potential advancement of science and treatments for diseases. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation actual timing and the research related to the new platform; uncertainty of success in the research efforts related to the platform; the risks of other unexpected hurdles, costs or delays; and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports it has filed with the U.S. Securities and Exchange Commission. These statements are based on Biogen's current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .

PFIZER DISCLOSURE NOTICE:
The information contained in this release is as of July 8, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a browser, "genebass.org", and its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, whether our collaboration with Biogen and AbbVie will be successful; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications for any potential drug candidates may be filed in any jurisdictions; whether and when regulatory authorities in any jurisdictions may approve any such applications, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such potential drug candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any such drug candidates; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About the UK Biobank
UK Biobank is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants.

UK Biobank's database, which includes blood samples, heart and brain scans and genetic data of the 500,000 volunteer participants, is globally accessible to approved researchers who are undertaking health-related research that's in the public interest.

UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the UK. With their consent, they provided detailed information about their lifestyle and physical measures and had blood, urine and saliva samples collected and stored for future analysis.

UK Biobank's research resource is a major contributor in the advancement of modern medicine and treatment, enabling better understanding of the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases and stroke. Since the UK Biobank resource was opened for research use in April 2012, over 20,000 researchers from 90+ countries have been approved to use it and more than 2,000 peer-reviewed papers that used the resource have now been published.

UK Biobank is generously supported by its founding funders the Wellcome Trust and UK Medical Research Council, as well as the British Heart Foundation, Cancer Research UK, Department of Health, Northwest Regional Development Agency and Scottish Government. The organisation has over 150 dedicated members of staff, based in multiple locations across the UK.

BIOGEN MEDIA CONTACT: BIOGEN INVESTOR CONTACT:
Allison Parks Mike Hencke
+1 781 464 3260 +1 781 464 2442
Public.affairs@biogen.com IR@biogen.com
PFIZER MEDIA CONTACT: PFIZER INVESTOR CONTACT:
Kit Longley Bryan Dunn
+1 929 930 0911 +1 212 733 8917
Kit.Longley@pfizer.com Bryan.Dunn@pfizer.com
ABBVIE MEDIA CONTACT: ABBVIE INVESTOR CONTACT:
Frank Benenati Liz Shea
+1 224 688 4169 +1 847 935 2211
frank.benenati@abbvie.com liz.shea@abbvie.com



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Bristol Myers Squibb Announces New Sotyktu Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu , a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis

New analysis to be presented at the 2022 European Academy of Dermatology and Venereology Congress as part of 26 company-sponsored scientific presentations, demonstrating ongoing commitment to dermatology research

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

  U.S. Food and Drug Administration Approves Sotyktu , Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

Bristol Myers Squibb's Sotyktu , a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years

Pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy of once-daily Sotyktu over placebo and twice-daily Otezla ® (apremilast) in improving skin clearance

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Gummy Project to Be Featured on "This Is BC" with Jay Durant on Global News Hour's Flagship Broadcast

The Gummy Project to Be Featured on "This Is BC" with Jay Durant on Global News Hour's Flagship Broadcast

  • The Gummy Project feature will be aired on Sunday, September 11, 2022 during the 6pm PST broadcast.
  • Global News Hour at 6 is one of B.C.'s most watched nightly newscasts and is the flagship news broadcast at Global BC.

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is excited to announce that it has been selected to be featured on Global News Hour's segment "This is BC" with Jay Durant during its flagship 6pm PST broadcast on Sunday, September 11, 2022.

"This is BC " with Jay Durant explores and uncovers the uplifting and unique stories of people, communities, places and business' in British Columbia and showcases the uniqueness of the province, the events that shape it and the people who live there. The segment airs during Global News Hour at 6pm PST on Tuesdays, Thursdays and Sundays weekly.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AbbVie Declares Quarterly Dividend

The board of directors of ABBVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.

The cash dividend is payable November 15, 2022 , to stockholders of record at the close of business on October 14, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 13, 2022 . Robert A. Bradway chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Strategic Entry into the United States Retail Market with Hy-Vee as First Grocery Retailer

The Gummy Project Announces Strategic Entry into the United States Retail Market with Hy-Vee as First Grocery Retailer

The Gummy Project  (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is excited to announce its entry into the U.S. market with Hy-Vee, Inc. as its first major retail partner.

The Gummy Project sells low-sugar, plant-based gummy products while raising money and awareness to support endangered species. For every bag of product purchased, GUMY donates a portion of the proceeds to help certain endangered species from going extinct.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×